tiprankstipranks
GENinCode Expands ROCA Test Access Across Switzerland
Company Announcements

GENinCode Expands ROCA Test Access Across Switzerland

GENinCode UK Ltd. (GB:GENI) has released an update.

Stay Ahead of the Market:

GENinCode has partnered with Genesupport SA to provide the ROCA Test for ovarian cancer surveillance across Switzerland, making it accessible to over 11,000 women at high risk. This collaboration aims to improve early detection and treatment outcomes, leveraging the ROCA Test’s proven accuracy and extensive clinical evaluation. The partnership is set to enhance preventive healthcare options for women with genetic predispositions to ovarian cancer.

For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles